MK 4464
Alternative Names: DF-8001; MK-4464Latest Information Update: 14 Oct 2022
At a glance
- Originator Dragonfly Therapeutics
- Developer Merck Sharp & Dohme
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Sep 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Israel (IV) (NCT05514444)
- 30 Sep 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Israel (IV) (NCT05514444)
- 30 Aug 2022 Preclinical trials in Solid tumours in USA (IV) before August 2022